Pfizer’s Norvasc Does Not Infringe Synthon Patent, Court Finds
This article was originally published in The Pink Sheet Daily
The company’s revenues stemming from its blockbuster hypertension treatment remain safe after Synthon had challenged its manufacturing process.
You may also be interested in...
Apotex will be prohibited from launching a generic of amlodipine until September 2007, according to a Jan. 18 ruling out of Chicago federal court
Mylan holds 180-day exclusivity on all three doses of Pfizer's Norvasc following FDA's confirmation that the generic firm was first-to-file on the 2.5 mg, 5 mg and 10 mg amlodipine doses, the company announced Oct. 4
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.